TriPath Imaging FDA revelation causes share slide
This article was originally published in Clinica
Executive Summary
US company TriPath Imaging, which is in distant second place to Cytyc in the enhanced Pap smear market, has made a voluntary declaration to the FDA. The statement concerns allegations by an unnamed former employee, questioning the use of the company's AutoPap screening system to screen thin layer cervical smear cytological specimens.